Search details
1.
Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophy.
Proc Natl Acad Sci U S A
; 117(18): 9952-9963, 2020 05 05.
Article
in English
| MEDLINE | ID: mdl-32345717
2.
Systems genomics in age-related macular degeneration.
Exp Eye Res
; 225: 109248, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36108770
3.
Conversion from Intermediate Age-Related Macular Degeneration to Geographic Atrophy in a Proxima B Subcohort Using a Multimodal Approach.
Ophthalmologica
; 244(6): 523-534, 2021.
Article
in English
| MEDLINE | ID: mdl-34348335
4.
Elevated IgE M1 prime transcripts in nasal tissues in patients with nasal polyps and asthma.
J Allergy Clin Immunol
; 143(2): 805-807, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30359682
5.
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Proc Natl Acad Sci U S A
; 107(29): 13075-80, 2010 Jul 20.
Article
in English
| MEDLINE | ID: mdl-20615965
6.
Alternative Complement Pathway Inhibition by Lampalizumab: Analysis of Data From Chroma and Spectri Phase III Clinical Trials.
Ophthalmol Sci
; 3(3): 100286, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37228694
7.
The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy: Analysis of the Phase III Chroma and Spectri Trials.
Ophthalmol Sci
; 3(4): 100301, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37304044
8.
Interreader Agreement and Longitudinal Progression of Incomplete/Complete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration.
Ophthalmol Retina
; 7(12): 1059-1068, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37517799
9.
Deep Learning to Predict Geographic Atrophy Area and Growth Rate from Multimodal Imaging.
Ophthalmol Retina
; 7(3): 243-252, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36038116
10.
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Ann Clin Transl Neurol
; 9(1): 50-66, 2022 01.
Article
in English
| MEDLINE | ID: mdl-35014217
11.
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
JAMA Neurol
; 79(11): 1113-1121, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-36121669
12.
Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration.
Am J Ophthalmol
; 232: 49-57, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34214452
13.
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
Alzheimers Res Ther
; 12(1): 16, 2020 01 22.
Article
in English
| MEDLINE | ID: mdl-31969177
14.
Preanalytical approaches to improve recovery of amyloid-ß peptides from CSF as measured by immunological or mass spectrometry-based assays.
Alzheimers Res Ther
; 10(1): 118, 2018 11 28.
Article
in English
| MEDLINE | ID: mdl-30486870
15.
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
JAMA Ophthalmol
; 136(6): 666-677, 2018 06 01.
Article
in English
| MEDLINE | ID: mdl-29801123
16.
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
Neurology
; 90(21): e1889-e1897, 2018 05 22.
Article
in English
| MEDLINE | ID: mdl-29695589
17.
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Alzheimers Res Ther
; 10(1): 96, 2018 09 19.
Article
in English
| MEDLINE | ID: mdl-30231896
18.
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.
Alzheimers Dement (N Y)
; 4: 150-160, 2018.
Article
in English
| MEDLINE | ID: mdl-29955659
19.
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Sci Transl Med
; 9(395)2017 06 21.
Article
in English
| MEDLINE | ID: mdl-28637922
20.
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
Proteomics Clin Appl
; 9(7-8): 715-31, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-25676562